Hemophilia of North Carolina

1-800-990-5557
(toll free)

Print This Article

Medical Advisory #423   CSL Behring Discontinues Production and Distribution of Monoclate-P®

NHF

March 20, 2018

CSL Behring has announced that due to patients transitioning from plasma-derived to recombinant products, it has been difficult to sustain the production and distribution of Antihemophilic Factor Monoclate-P® Factor VIII:C Pasteurized Monoclonal Antibody Purified. Therefore production of Monoclate-P® will be discontinued, and CSL Behring estimates that existing supplies will only be available until December 2018.

If you are currently using Monoclate-P®, please contact your physician or hemophilia treatment center to learn about other options that are available to you for treatment.


PHYSICIANS: Please distribute this information to all providers in your area who treat patients with hemophilia.

CHAPTERS: Please distribute this information to your membership.

Please sign up for the Patient Notification System (PNS) to be notified directly about the latest recall or withdrawal of recombinant and plasma products. The system is confidential and time sensitive. It is administered by an independent third-party organization and is free of charge. To enroll in the PNS, please call (888) UPDATE-U or go online at: www.patientnotificationsystem.org.

This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends treatment for specific individuals and in all cases recommends that you consult your physician or local hemophilia treatment center before pursuing any course of treatment.